search
Back to results

Rudi Kundini, Pamoja Kundini: Phase I (RKPK: Phase I)

Primary Purpose

HIV (Human Immunodeficiency Virus)

Status
Recruiting
Phase
Not Applicable
Locations
Tanzania
Study Type
Interventional
Intervention
Conditional Cash Transfer
Sponsored by
University of California, Berkeley
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for HIV (Human Immunodeficiency Virus) focused on measuring Conditional Cash Transfers, Tanzania, People Living With HIV

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. PLHIV living in the catchment area of a study health facility;
  2. Age 18 years or older;
  3. Phone ownership OR phone consistent phone access;
  4. Classified as lost to follow up (LTFU) from HIV care (not attended a clinic appointment for ≥28 days since last scheduled appointment);
  5. Has had a clinic appointment within the last 12 months, and
  6. Provides written informed consent for participation

Sites / Locations

  • Geita RegionRecruiting
  • Kagera RegionRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Conditional Cash Transfer

Control

Arm Description

Eligible and consenting participants living in an intervention health facility catchment area will receive the same standard of care HIV tracing and clinical services as control participants, plus the opportunity to receive a one-time incentive of 22,500 Tanzanian Shillings (TSH) (~$10), with half (11,250 TSH) delivered upon enrollment in the study and half delivered after confirmation of the completion of a clinical visit if within 90 days of study enrollment.

Eligible and consenting participants living in a control health facility catchment area will receive the standard of care HIV tracing and clinical services.

Outcomes

Primary Outcome Measures

6-month Viral Suppression
The proportion of people living with HIV (PLHIV) retained in HIV primary care and with suppressed HIV viral load 6 months following study enrollment. The primary outcome is expressed as a binary variable, defined as PLHIV who are on ART and with sufficient HIV viral suppression (<1000 copies/ml, WHO's threshold for virologic failure in LMICs) versus not on ART or viral failure (≥1000 copies/ml).

Secondary Outcome Measures

12-month Viral Suppression
The proportion of people living with HIV (PLHIV) retained in HIV primary care and with suppressed HIV viral load 12 months following study enrollment. The primary outcome is expressed as a binary variable, defined as PLHIV who are on ART and with sufficient HIV viral suppression (<1000 copies/ml, the World Health Organization (WHO) threshold for virologic failure in low- and middle-income countries (LMIC)) versus not on ART or viral failure (≥1000 copies/ml).
Durable 12-month Viral Suppression
The proportion of people living with HIV (PLHIV) with durable HIV viral suppression at 12 months after study enrollment months (either: 1) ≥2 assessments of viral load, taken from up to 6 months prior to study enrollment and up to and including 12 months following study enrollment (the recommended timing of immunologic monitoring for stable PLHIV on ART with viral suppression), or 2) ≥3 assessments if baseline viral load is >1000 copies/ml (the recommended timing of immunologic monitoring mandates an additional follow-up assessment 3 months and again at 12 months)
6-month Appointment Attendance
The proportion of scheduled visits that were completed during the 0-6 month period
12-month Appointment Attendance
The proportion of scheduled visits that were completed during the 0-12 month period
12-month Mortality
The cumulative incidence of mortality at 12 months after study enrollment
Incidence of viral suppression
The cumulative incidence of mortality at 12 months after study enrollment
Incidence of re-linkage to HIV care
The cumulative incidence of re-linkage to to HIV care at 12 months after study enrollment
Time to re-linkage to HIV care
Time for patients to re-link back to HIV care
6 month retention in care
The proportion of people living with HIV (PLHIV) on ART at 6 months after study enrollment (PEPFAR considers those not retained on ART to include those who died, disengaged from care, stopped ART, or had no evidence of care for ≥28 days after a missed visit. Participants not found after exhaustive tracing efforts to rule out silent transfers will be classified as not retained on ART)
12 month retention in care
The proportion of people living with HIV (PLHIV) on ART at 12 months after study enrollment (PEPFAR considers those not retained on ART to include those who died, disengaged from care, stopped ART, or had no evidence of care for ≥28 days after a missed visit. Participants not found after exhaustive tracing efforts to rule out silent transfers will be classified as not retained on ART)

Full Information

First Posted
February 9, 2022
Last Updated
May 30, 2023
Sponsor
University of California, Berkeley
Collaborators
Health for a Prosperous Nation, Rasello, Management and Development for Health, Ministry of Health, Tanzania, National Institute of Mental Health (NIMH)
search

1. Study Identification

Unique Protocol Identification Number
NCT05248100
Brief Title
Rudi Kundini, Pamoja Kundini: Phase I
Acronym
RKPK: Phase I
Official Title
Strengthening the Continuity of HIV Care in Tanzania With Economic Support: Phase I
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 25, 2022 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
October 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of California, Berkeley
Collaborators
Health for a Prosperous Nation, Rasello, Management and Development for Health, Ministry of Health, Tanzania, National Institute of Mental Health (NIMH)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This protocol describes a 2-arm cluster, randomized controlled trial designed to test the effectiveness of a conditional cash transfer on viral suppression at 6 months among people living with HIV infection (PLHIV) in Tanzania who have disengaged from HIV care. Randomization will take place at the clinic level (HIV primary care clinics). The comparison group receives standard of care standard of care HIV tracing services according to Tanzania's National Guidelines for the Management of HIV and the Ministry of Health to locate potential participants, including home based care (HBC) tracing of PLHIV who have disengaged from primary care, the provision of counseling to return to HIV care, and the offer to schedule an HIV primary care appointment on the spot. Eligible adult PLHIV disengaged from HIV care and living in an intervention facility catchment area will receive the same standard of care HIV tracing and clinical services as control participants, plus the opportunity to receive a one-time cash transfer incentive, conditional upon confirmed completion of a clinical visit if within 90 days of study enrollment. The primary endpoint is viral suppression (<1000 copies/ml) at 6 months after study enrollment.
Detailed Description
The overall objective of this study is to evaluate the effectiveness of a home visit plus one-time financial incentive on the proportion of out of care PLHIV with viral load suppression (<1000 copies/ml) at 6 months after study enrollment. We will use a cluster, randomized controlled trial design with a sample size of 20 PLHIV in each of the 32 health facility catchment areas (N=640 PLHIV total) to examine the effect of a home visit plus one-time financial incentive on the primary outcome of viral suppression at 6 months. The study will take place across Geita and Kagera Regions (Lake Zone) in Tanzania. This study will follow standard of care HIV tracing services according to Tanzania's National Guidelines for the Management of HIV and the Ministry of Health to locate potential participants, including home based care (HBC) tracing of PLHIV who have disengaged from primary care, the provision of counseling to return to HIV care, and the offer to schedule an HIV primary care appointment on the spot. Eligible and consenting participants living in an intervention health facility catchment area will receive the same standard of care HIV tracing and clinical services as control participants, plus the opportunity to receive a one-time incentive of 22,500 TSH (~$10 USD), with half (11,250 TSH) delivered upon enrollment in the study and half delivered after confirmation of the completion of a clinical visit if within 90 days of study enrollment. Primary Endpoint: 1. Viral suppression (<1000 copies/ml) at 6 months after enrollment Secondary Endpoints: Viral suppression at 12 months after enrollment Durable viral suppression at 12 months after enrollment Appointment attendance Time to re-linkage to care Mortality at 12 months after enrollment Re-linkage to care at 12 months after enrollment Retention at 6 and 12 months, defined as the proportion of PLHIV on antiretroviral therapy (ART) at 6 months after enrollment and 12 months after enrollment, respectively

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV (Human Immunodeficiency Virus)
Keywords
Conditional Cash Transfers, Tanzania, People Living With HIV

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Masking Description
Participants will not be told during the consent process that as part of the study there are intervention and control clinics. Laboratory staff analyzing viral load samples will be blind to intervention/control attribution.
Allocation
Randomized
Enrollment
640 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Conditional Cash Transfer
Arm Type
Experimental
Arm Description
Eligible and consenting participants living in an intervention health facility catchment area will receive the same standard of care HIV tracing and clinical services as control participants, plus the opportunity to receive a one-time incentive of 22,500 Tanzanian Shillings (TSH) (~$10), with half (11,250 TSH) delivered upon enrollment in the study and half delivered after confirmation of the completion of a clinical visit if within 90 days of study enrollment.
Arm Title
Control
Arm Type
No Intervention
Arm Description
Eligible and consenting participants living in a control health facility catchment area will receive the standard of care HIV tracing and clinical services.
Intervention Type
Behavioral
Intervention Name(s)
Conditional Cash Transfer
Intervention Description
The intervention is a one-time cash transfer of 22,500 Tanzanian Shillings (~$10), with half (11,250 TSH) delivered upon enrollment in the study and half delivered after confirmation of the completion of a clinical visit if within 90 days of study enrollment.
Primary Outcome Measure Information:
Title
6-month Viral Suppression
Description
The proportion of people living with HIV (PLHIV) retained in HIV primary care and with suppressed HIV viral load 6 months following study enrollment. The primary outcome is expressed as a binary variable, defined as PLHIV who are on ART and with sufficient HIV viral suppression (<1000 copies/ml, WHO's threshold for virologic failure in LMICs) versus not on ART or viral failure (≥1000 copies/ml).
Time Frame
6 months
Secondary Outcome Measure Information:
Title
12-month Viral Suppression
Description
The proportion of people living with HIV (PLHIV) retained in HIV primary care and with suppressed HIV viral load 12 months following study enrollment. The primary outcome is expressed as a binary variable, defined as PLHIV who are on ART and with sufficient HIV viral suppression (<1000 copies/ml, the World Health Organization (WHO) threshold for virologic failure in low- and middle-income countries (LMIC)) versus not on ART or viral failure (≥1000 copies/ml).
Time Frame
12 months
Title
Durable 12-month Viral Suppression
Description
The proportion of people living with HIV (PLHIV) with durable HIV viral suppression at 12 months after study enrollment months (either: 1) ≥2 assessments of viral load, taken from up to 6 months prior to study enrollment and up to and including 12 months following study enrollment (the recommended timing of immunologic monitoring for stable PLHIV on ART with viral suppression), or 2) ≥3 assessments if baseline viral load is >1000 copies/ml (the recommended timing of immunologic monitoring mandates an additional follow-up assessment 3 months and again at 12 months)
Time Frame
12 months
Title
6-month Appointment Attendance
Description
The proportion of scheduled visits that were completed during the 0-6 month period
Time Frame
6 months
Title
12-month Appointment Attendance
Description
The proportion of scheduled visits that were completed during the 0-12 month period
Time Frame
12 months
Title
12-month Mortality
Description
The cumulative incidence of mortality at 12 months after study enrollment
Time Frame
12 months
Title
Incidence of viral suppression
Description
The cumulative incidence of mortality at 12 months after study enrollment
Time Frame
12 months
Title
Incidence of re-linkage to HIV care
Description
The cumulative incidence of re-linkage to to HIV care at 12 months after study enrollment
Time Frame
12 months
Title
Time to re-linkage to HIV care
Description
Time for patients to re-link back to HIV care
Time Frame
12 months
Title
6 month retention in care
Description
The proportion of people living with HIV (PLHIV) on ART at 6 months after study enrollment (PEPFAR considers those not retained on ART to include those who died, disengaged from care, stopped ART, or had no evidence of care for ≥28 days after a missed visit. Participants not found after exhaustive tracing efforts to rule out silent transfers will be classified as not retained on ART)
Time Frame
6 months
Title
12 month retention in care
Description
The proportion of people living with HIV (PLHIV) on ART at 12 months after study enrollment (PEPFAR considers those not retained on ART to include those who died, disengaged from care, stopped ART, or had no evidence of care for ≥28 days after a missed visit. Participants not found after exhaustive tracing efforts to rule out silent transfers will be classified as not retained on ART)
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: PLHIV living in the catchment area of a study health facility; Age 18 years or older; Phone ownership OR phone consistent phone access; Classified as lost to follow up (LTFU) from HIV care (not attended a clinic appointment for ≥28 days since last scheduled appointment); Has had a clinic appointment within the last 24 months, and Provides written informed consent for participation
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sandra I McCoy, PhD, MPH
Phone
+15106420513
Email
smccoy@berkeley.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sandra I McCoy, PhD, MPH
Organizational Affiliation
University of California, Berkeley
Official's Role
Principal Investigator
Facility Information:
Facility Name
Geita Region
City
Geita
Country
Tanzania
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amon Sabasaba, MD, MSc
Facility Name
Kagera Region
City
Kagera
Country
Tanzania
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amon Sabasaba, MD, MSc

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Provided upon request
IPD Sharing Access Criteria
Provided upon request

Learn more about this trial

Rudi Kundini, Pamoja Kundini: Phase I

We'll reach out to this number within 24 hrs